RecruitingPhase 2NCT05775718

Shingrix In Recipients of Allogeneic Transplants

Safety and Immunogenicity of Shingrix Administered to Recipients of Allogeneic Peripheral and Cord Blood Stem Cell Transplants: Effect of Timing of Vaccination After Transplantation

Sponsor

University of Colorado, Denver

Enrollment

55 participants

Start Date

Oct 24, 2023

Study Type

INTERVENTIONAL

Conditions

Bone Marrow Transplant Stem Cell Transplant

Summary

This research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant (allo-SCT). Specifically, it will determine the effect of the interval after transplantation on the immune response and if an additional dose of vaccine is needed to improve the vaccine-induced responses.

Eligibility

Min Age: 18 YearsMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Zoster Vaccine Recombinant for people with bone marrow transplant and stem cell transplant. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 79 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.